

Annalisa Paviglianiti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4427812/publications.pdf>

Version: 2024-02-01

39
papers

608
citations

759233

12
h-index

610901

24
g-index

39
all docs

39
docs citations

39
times ranked

1372
citing authors

#	ARTICLE	IF	CITATIONS
1	Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. <i>Supportive Care in Cancer</i> , 2022, 30, 585-591.	2.2	4
2	Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 443-449.	1.3	0
3	Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 419-427.	1.3	9
4	The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e402-e409.	0.4	4
5	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1077-1085.	2.4	4
6	An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1025-1034.	3.1	4
7	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <i>JACC: CardioOncology</i> , 2021, 3, 250-259.	4.0	48
8	Allogeneic stem cell transplantation in multiple myeloma: dead or alive and kicking?. <i>Panminerva Medica</i> , 2021, 62, 234-243.	0.8	3
9	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 377-382.	0.4	10
10	Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102911.	1.0	0
11	High-dose post-transplant cyclophosphamide impairs T cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. <i>Clinical and Translational Immunology</i> , 2020, 9, e1171.	3.8	9
12	Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. <i>Frontiers in Oncology</i> , 2020, 10, 592487.	2.8	7
13	Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 791-796.	0.4	6
14	Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience. <i>Cytotherapy</i> , 2020, 22, 445-449.	0.7	8
15	COVID-19 outcomes in patients with hematologic disease. <i>Bone Marrow Transplantation</i> , 2020, 55, 2180-2184.	2.4	138
16	Calcineurin Inhibitor Alone or in Combination with Mycophenolate Mofetil for Graft-Versus-Host-Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Transplantation from Matched Unrelated Donors: A Study from the ALWP of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S56-S57.	2.0	0
17	<p>A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 205-212.	1.7	2
18	Endocrine and Metabolic Disorders After Hematopoietic Stem Cell Transplantation Annalisa Paviglianiti <i>Metabolic Diseases in Hematology. Turkish Journal of Haematology</i> , 2020, 37, 111-115.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Stable Pulmonary Function after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide: A Single Center Experience. <i>Blood</i> , 2020, 136, 30-30.	1.4	0
20	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1987-1994.	2.4	25
21	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1407-1415.	2.0	42
22	Impact of cyclosporine A concentration on acute graft-versus-host disease incidence after haploidentical hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 10-17.	2.2	17
23	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2019, 184, 397-404.	2.5	10
24	Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT. <i>Blood</i> , 2019, 134, 4548-4548.	1.4	0
25	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1407-1415.	2.0	11
26	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 799-805.	2.0	22
27	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. <i>Blood Advances</i> , 2018, 2, 49-60.	5.2	45
28	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
29	Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Medicinal Chemistry</i> , 2018, 25, 4535-4544.	2.4	12
30	Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks. <i>Haematologica</i> , 2017, 102, 976-983.	3.5	8
31	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. <i>British Journal of Haematology</i> , 2017, 179, 790-801.	2.5	9
32	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	4.6	72
33	Impact of HLA in cord blood transplantation outcomes. <i>Hla</i> , 2016, 87, 413-421.	0.6	31
34	Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 1120-1127.	3.5	16
35	Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1997-2002.	2.0	17
36	Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. <i>Blood</i> , 2016, 128, 3484-3484.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. Blood, 2015, 126, 3214-3214.	1.4	1
38	Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study. Blood, 2015, 126, 3203-3203.	1.4	0
39	A Case of Transplantation-Associated Thrombotic Microangiopathy with Cardiac Involvement Successfully Treated with Plasma Exchange. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 369-371.	0.6	3